Louisiana State Employees Retirement System Takes Position in Enovis Corporation $ENOV

Louisiana State Employees Retirement System acquired a new position in Enovis Corporation (NYSE:ENOV) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 25,400 shares of the company’s stock, valued at approximately $578,000.

Other hedge funds also recently added to or reduced their stakes in the company. OP Asset Management Ltd purchased a new stake in Enovis in the first quarter valued at about $931,000. River Road Asset Management LLC increased its holdings in shares of Enovis by 3.2% during the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after acquiring an additional 46,289 shares in the last quarter. Corient Private Wealth LLC increased its holdings in shares of Enovis by 540.7% during the fourth quarter. Corient Private Wealth LLC now owns 55,180 shares of the company’s stock valued at $1,470,000 after acquiring an additional 46,568 shares in the last quarter. Front Street Capital Management Inc. raised its position in shares of Enovis by 75.8% in the 4th quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company’s stock valued at $9,642,000 after purchasing an additional 156,069 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Enovis in the 4th quarter valued at approximately $561,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Enovis

In related news, insider Oliver Engert acquired 1,200 shares of Enovis stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the purchase, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders bought 4,200 shares of company stock worth $92,084. Company insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on ENOV shares. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research note on Monday. BTIG Research reissued a “buy” rating and set a $39.00 price objective on shares of Enovis in a report on Friday, May 22nd. Wells Fargo & Company cut their target price on Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. William Blair assumed coverage on Enovis in a research note on Friday, April 17th. They issued an “outperform” rating for the company. Finally, Zacks Research downgraded Enovis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, June 30th. Seven analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.83.

Enovis Stock Down 1.3%

ENOV stock opened at $25.56 on Wednesday. The company has a market capitalization of $1.47 billion, a P/E ratio of -1.29 and a beta of 1.39. Enovis Corporation has a 12 month low of $19.14 and a 12 month high of $36.82. The firm’s fifty day simple moving average is $23.32 and its 200-day simple moving average is $23.83. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.07. The firm had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities research analysts forecast that Enovis Corporation will post 3.12 earnings per share for the current year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.